论文部分内容阅读
目的重点了解痛风伴高尿酸血症病例中施予非布司他疗法的必要性。方法抽取95例患有痛风而于2015年3月—2016年8月间进入该院的患者,均并发高尿酸血症,且依据两种不同用药疗法分组:46例甲组病例均施予别嘌呤醇疗法,49例乙组则施予非布司他疗法,给予两组病例用药疗效、血尿酸值及其不良症状分别统计。结果给予甲组与乙组病例分别实施不同疗法后,46例甲组病例总有效率76.09%(35/46),49例乙组是93.88%(46/49),(P<0.05);甲组内有4例(8.70%)出现不良症状,而乙组有3例(6.12%),(P>0.05),且乙组病例病例血尿酸值则优于甲组(P<0.05)。结论对于并发高尿酸血症的痛风病例,予以用药非布司他表现出有效性强、安全性高等优势,值得推荐。
Purpose To focus on the need for the administration of febuxostat to gout with hyperuricemia. Methods A total of 95 patients with gout who entered the hospital between March 2015 and August 2016 were enrolled in this study. All patients were complicated with hyperuricemia and were divided into two groups according to two different medication regimens: 46 patients in group A Purinol therapy, 49 cases of group B was given febuxostat therapy, given two groups of patients efficacy, uric acid value and its adverse symptoms statistics. Results After giving different treatments to group A and group B respectively, the total effective rate in group A was 76.09% (35/46) and that in group B was 93.88% (46/49) (P <0.05). A There were 4 cases (8.70%) with adverse symptoms in group B, 3 cases (6.12%) in group B (P> 0.05), and those in group B were better than those in group A (P <0.05). Conclusions For patients with gout complicated by hyperuricemia, it should be recommended to use the drug febuxostat to be effective and safe.